Keywords: capoten, gains, additional, license, uk, bristol-myers, squibb
CAPOTEN GAINS ADDITIONAL LICENSE IN UK
Article | 21 February 1994
- Bristol-Myers Squibb's Capoten (captopril) has been licensed for use in preventing heart failure, and Merck Sharp & Dohme's Innovace (enalapril) is ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
